ArticleLeukemia & lymphoma2020

Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

Prajwal Dhakal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.